Daiichi Sankyo Company, Limited
4568
Classifica tra le azioni
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Prezzo delle azioni
$18.01
Capitalizzazione di mercato
$32.77B
Variazione (1 giorno)
0.14%
Variazione (1 anno)
-30.22%
Paese
JP
Scambia Daiichi Sankyo Company, Limited (4568)
Categoria
Healthcare
Ricavi di Daiichi Sankyo Company, Limited (4568)
Ricavi nel Oct 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Daiichi Sankyo Company, Limited, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Daiichi Sankyo Company, Limited da 2001 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2025 | $12.58B | 18.91% |
| 2024 | $10.58B | 9.90% |
| 2023 | $9.63B | 12.20% |
| 2022 | $8.58B | -1.25% |
| 2021 | $8.69B | -4.84% |
| 2020 | $9.13B | 9.03% |
| 2019 | $8.38B | -7.32% |
| 2018 | $9.04B | 5.39% |
| 2017 | $8.58B | -2.19% |
| 2016 | $8.77B | 14.38% |
| 2015 | $7.67B | -12.07% |
| 2014 | $8.72B | -17.41% |
| 2013 | $10.56B | -6.71% |
| 2012 | $11.31B | -3.05% |
| 2011 | $11.67B | 14.54% |
| 2010 | $10.19B | 19.06% |
| 2009 | $8.56B | -3.04% |
| 2008 | $8.83B | 12.02% |
| 2007 | $7.88B | 0.11% |
| 2006 | $7.87B | 43.33% |
| 2005 | $5.49B | -4.11% |
| 2004 | $5.73B | 18.80% |
| 2003 | $4.82B | 16.37% |
| 2002 | $4.14B | -4.69% |
| 2001 | $4.35B | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $79.67B | - |
US
|
|
| $99.34B | - |
US
|
|
| $64.39B | - |
US
|
|
| $66.40B | - |
US
|
|
| $77.52B | - |
CH
|
